MX362912B - Péptidos ube2t y vacunas que incluyen los mismos. - Google Patents
Péptidos ube2t y vacunas que incluyen los mismos.Info
- Publication number
- MX362912B MX362912B MX2015003017A MX2015003017A MX362912B MX 362912 B MX362912 B MX 362912B MX 2015003017 A MX2015003017 A MX 2015003017A MX 2015003017 A MX2015003017 A MX 2015003017A MX 362912 B MX362912 B MX 362912B
- Authority
- MX
- Mexico
- Prior art keywords
- ube2t
- methods
- peptides
- ctls
- inducing
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699550P | 2012-09-11 | 2012-09-11 | |
| PCT/JP2013/005321 WO2014041784A1 (en) | 2012-09-11 | 2013-09-09 | Ube2t peptides and vaccines containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003017A MX2015003017A (es) | 2015-06-10 |
| MX362912B true MX362912B (es) | 2019-02-22 |
Family
ID=50277926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003017A MX362912B (es) | 2012-09-11 | 2013-09-09 | Péptidos ube2t y vacunas que incluyen los mismos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10092634B2 (enExample) |
| EP (1) | EP2895600B1 (enExample) |
| JP (1) | JP6283861B2 (enExample) |
| KR (1) | KR102110873B1 (enExample) |
| CN (2) | CN104619833B (enExample) |
| AU (1) | AU2013317194B2 (enExample) |
| BR (1) | BR112015004349B1 (enExample) |
| CA (1) | CA2873155C (enExample) |
| DK (1) | DK2895600T3 (enExample) |
| ES (1) | ES2784862T3 (enExample) |
| IL (1) | IL236690B (enExample) |
| MX (1) | MX362912B (enExample) |
| PL (1) | PL2895600T3 (enExample) |
| RU (1) | RU2663350C2 (enExample) |
| SG (2) | SG11201501761SA (enExample) |
| TW (1) | TWI632162B (enExample) |
| WO (1) | WO2014041784A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12098387B2 (en) | 2015-10-19 | 2024-09-24 | University Of Maryland, Baltimore | Methods for generating engineered human primary blood dendritic cell lines |
| JP6715004B2 (ja) | 2015-12-25 | 2020-07-01 | 宏 半田 | 免疫賦活化剤およびその製造方法 |
| LT3573600T (lt) | 2017-01-25 | 2022-06-27 | Ose Immunotherapeutics | Peptidų pristatymui skirtos stabilios emulsijos gamybos būdas |
| AU2018346765B2 (en) * | 2017-10-06 | 2025-02-06 | Oncotherapy Science, Inc. | Screening of T lymphocytes for cancer-specific antigens |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN113679829B (zh) | 2020-05-18 | 2024-01-02 | 北京繁易纳维科技有限公司 | 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU749544B2 (en) | 1998-06-25 | 2002-06-27 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen peptides originating in cyclophilin B |
| TW200728465A (en) | 1998-07-14 | 2007-08-01 | Corixa Corp | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO2000020027A2 (en) | 1998-10-05 | 2000-04-13 | M & E Biotech A/S | Methods for therapeutic vaccination |
| US6468546B1 (en) * | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| JP4900884B2 (ja) | 2000-07-31 | 2012-03-21 | 株式会社グリーンペプタイド | 腫瘍抗原 |
| TW200512298A (en) | 2003-09-24 | 2005-04-01 | Oncotherapy Science Inc | Method of diagnosing breast cancer |
| US20070202109A1 (en) | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
| WO2008102906A1 (en) | 2007-02-20 | 2008-08-28 | Oncotherapy Science, Inc. | Hspc-hrpc transition genes |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| WO2010032696A1 (ja) * | 2008-09-18 | 2010-03-25 | 学校法人慶應義塾 | がんの診断方法と治療方法 |
| TWI539160B (zh) * | 2008-12-05 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| CA2747686A1 (en) * | 2008-12-24 | 2010-07-01 | Oncotherapy Science, Inc. | C1orf59 peptides and vaccines including the same |
| TW201102081A (en) * | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| TW201216982A (en) * | 2010-10-21 | 2012-05-01 | Oncotherapy Science Inc | WDHD1 peptides and vaccines including the same |
| BR112013009276A2 (pt) * | 2010-10-21 | 2019-09-24 | Oncotherapy Science Inc | peptídeos de c18orf54 e vacinas incluindo os mesmos |
| CN105111281A (zh) * | 2010-12-02 | 2015-12-02 | 肿瘤疗法科学股份有限公司 | Tomm34肽及包含它们的疫苗 |
-
2013
- 2013-09-09 US US14/400,169 patent/US10092634B2/en active Active
- 2013-09-09 BR BR112015004349-6A patent/BR112015004349B1/pt not_active IP Right Cessation
- 2013-09-09 JP JP2015530559A patent/JP6283861B2/ja active Active
- 2013-09-09 SG SG11201501761SA patent/SG11201501761SA/en unknown
- 2013-09-09 SG SG10201701866QA patent/SG10201701866QA/en unknown
- 2013-09-09 WO PCT/JP2013/005321 patent/WO2014041784A1/en not_active Ceased
- 2013-09-09 EP EP13837757.7A patent/EP2895600B1/en active Active
- 2013-09-09 PL PL13837757T patent/PL2895600T3/pl unknown
- 2013-09-09 CA CA2873155A patent/CA2873155C/en active Active
- 2013-09-09 RU RU2015113436A patent/RU2663350C2/ru active
- 2013-09-09 DK DK13837757.7T patent/DK2895600T3/da active
- 2013-09-09 CN CN201380047407.3A patent/CN104619833B/zh not_active Expired - Fee Related
- 2013-09-09 ES ES13837757T patent/ES2784862T3/es active Active
- 2013-09-09 CN CN201711214045.9A patent/CN107881158B/zh not_active Expired - Fee Related
- 2013-09-09 AU AU2013317194A patent/AU2013317194B2/en not_active Ceased
- 2013-09-09 MX MX2015003017A patent/MX362912B/es active IP Right Grant
- 2013-09-09 KR KR1020147031506A patent/KR102110873B1/ko not_active Expired - Fee Related
- 2013-09-10 TW TW102132531A patent/TWI632162B/zh not_active IP Right Cessation
-
2015
- 2015-01-13 IL IL236690A patent/IL236690B/en active IP Right Grant
-
2018
- 2018-08-31 US US16/120,102 patent/US11266729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| MX2016014711A (es) | Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma). | |
| GB201004575D0 (en) | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers | |
| EP3708185A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| BR112015021828A2 (pt) | Peptídeos de kntc2 e vacinas que contêm os mesmos | |
| PH12014500720A1 (en) | Topk peptides and vaccines including the same | |
| MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
| MX2012008657A (es) | Peptidos melk modificados y vacunas que contienen los mismos. | |
| MX2022006022A (es) | Peptido derivado de depdc1 y vacuna que lo contiene. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| EP3590954A3 (en) | Koc1-derived peptide and vaccine including same | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| EP3848383A3 (en) | Urlc10-derived peptide and vaccine containing same | |
| EP4282883A3 (en) | Cdca1-derived peptide and vaccine containing same | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
| MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |